| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 12 | 2024 | 330 | 3.030 |
Why?
|
| Brain Neoplasms | 22 | 2025 | 1216 | 2.960 |
Why?
|
| Aurora Kinase A | 6 | 2023 | 39 | 2.750 |
Why?
|
| Neoplasms, Neuroepithelial | 4 | 2023 | 12 | 2.730 |
Why?
|
| Glioma | 8 | 2023 | 492 | 1.590 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2019 | 188 | 1.450 |
Why?
|
| Azepines | 5 | 2023 | 63 | 1.440 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2023 | 197 | 1.310 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2023 | 468 | 1.190 |
Why?
|
| Ependymoma | 6 | 2016 | 125 | 1.160 |
Why?
|
| Supratentorial Neoplasms | 2 | 2023 | 36 | 1.090 |
Why?
|
| Pyrimidines | 4 | 2019 | 373 | 1.030 |
Why?
|
| Apoptosis | 5 | 2023 | 1806 | 0.990 |
Why?
|
| Neurilemmoma | 1 | 2025 | 44 | 0.920 |
Why?
|
| DNA-Binding Proteins | 2 | 2025 | 2048 | 0.830 |
Why?
|
| Mutation | 10 | 2025 | 5845 | 0.820 |
Why?
|
| Taxoids | 2 | 2023 | 67 | 0.780 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 541 | 0.770 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2021 | 1 | 0.760 |
Why?
|
| Drug Synergism | 2 | 2019 | 228 | 0.750 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 5 | 2008 | 28 | 0.750 |
Why?
|
| Biomarkers, Tumor | 9 | 2016 | 1496 | 0.740 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 52 | 0.730 |
Why?
|
| Neural Stem Cells | 1 | 2022 | 119 | 0.710 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 1691 | 0.680 |
Why?
|
| Adenoma | 2 | 2019 | 129 | 0.640 |
Why?
|
| DNA Repair Enzymes | 1 | 2019 | 39 | 0.630 |
Why?
|
| DNA Modification Methylases | 1 | 2019 | 44 | 0.630 |
Why?
|
| Trans-Activators | 2 | 2023 | 798 | 0.630 |
Why?
|
| Ovary | 1 | 2021 | 380 | 0.620 |
Why?
|
| Cerebral Cortex | 2 | 2016 | 452 | 0.590 |
Why?
|
| Boron Neutron Capture Therapy | 1 | 2017 | 1 | 0.560 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2017 | 1 | 0.560 |
Why?
|
| Cushing Syndrome | 1 | 2017 | 16 | 0.550 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2017 | 74 | 0.550 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2017 | 43 | 0.550 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2017 | 76 | 0.550 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 320 | 0.550 |
Why?
|
| Breast | 2 | 2023 | 213 | 0.530 |
Why?
|
| Ubiquitin | 2 | 2009 | 141 | 0.520 |
Why?
|
| Granuloma | 1 | 2017 | 68 | 0.520 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2010 | 72 | 0.520 |
Why?
|
| Humans | 67 | 2025 | 125189 | 0.520 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 79 | 0.520 |
Why?
|
| Vestibular Diseases | 1 | 2017 | 67 | 0.510 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2009 | 262 | 0.510 |
Why?
|
| Face | 1 | 2017 | 179 | 0.500 |
Why?
|
| Cell Line, Tumor | 11 | 2023 | 3348 | 0.490 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 152 | 0.490 |
Why?
|
| Carcinoma | 2 | 2017 | 287 | 0.490 |
Why?
|
| Oximes | 1 | 2015 | 55 | 0.480 |
Why?
|
| Epilepsies, Partial | 1 | 2016 | 91 | 0.480 |
Why?
|
| Transcription Factors | 2 | 2025 | 2593 | 0.470 |
Why?
|
| Choroid Plexus Neoplasms | 2 | 2016 | 13 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1251 | 0.470 |
Why?
|
| F-Box Proteins | 4 | 2008 | 34 | 0.470 |
Why?
|
| Astrocytoma | 1 | 2015 | 100 | 0.460 |
Why?
|
| Imidazoles | 1 | 2015 | 203 | 0.450 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 779 | 0.450 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 265 | 0.440 |
Why?
|
| Dacarbazine | 1 | 2014 | 95 | 0.430 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 185 | 0.430 |
Why?
|
| Immunohistochemistry | 12 | 2016 | 1693 | 0.430 |
Why?
|
| Cell Lineage | 2 | 2022 | 345 | 0.430 |
Why?
|
| Genomics | 2 | 2019 | 1499 | 0.420 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 302 | 0.420 |
Why?
|
| Female | 35 | 2024 | 66806 | 0.410 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 667 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1140 | 0.390 |
Why?
|
| RNA, Small Interfering | 4 | 2023 | 663 | 0.380 |
Why?
|
| Gliosarcoma | 2 | 2010 | 10 | 0.370 |
Why?
|
| Pathology, Surgical | 1 | 2011 | 19 | 0.370 |
Why?
|
| Abnormalities, Multiple | 1 | 2017 | 960 | 0.360 |
Why?
|
| Cell Cycle Proteins | 5 | 2008 | 656 | 0.360 |
Why?
|
| Research Report | 1 | 2011 | 75 | 0.350 |
Why?
|
| Tuberculosis | 1 | 2017 | 526 | 0.350 |
Why?
|
| Brain | 6 | 2017 | 2999 | 0.350 |
Why?
|
| Cell Differentiation | 4 | 2014 | 1898 | 0.340 |
Why?
|
| Pituitary Neoplasms | 2 | 2019 | 80 | 0.340 |
Why?
|
| Choroid Plexus | 1 | 2010 | 23 | 0.340 |
Why?
|
| Middle Aged | 21 | 2024 | 26927 | 0.340 |
Why?
|
| Cerebrospinal Fluid | 1 | 2010 | 93 | 0.330 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 70 | 0.330 |
Why?
|
| Tissue Array Analysis | 3 | 2008 | 137 | 0.320 |
Why?
|
| Male | 27 | 2025 | 61525 | 0.310 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 272 | 0.310 |
Why?
|
| Phenotype | 3 | 2017 | 4262 | 0.300 |
Why?
|
| Ubiquitination | 1 | 2009 | 167 | 0.300 |
Why?
|
| Ependyma | 1 | 2008 | 7 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2023 | 1893 | 0.290 |
Why?
|
| Young Adult | 10 | 2024 | 9053 | 0.290 |
Why?
|
| Child | 12 | 2024 | 24421 | 0.280 |
Why?
|
| Prognosis | 5 | 2023 | 4645 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 618 | 0.280 |
Why?
|
| Adult | 19 | 2024 | 29628 | 0.280 |
Why?
|
| Melanocytes | 1 | 2007 | 48 | 0.280 |
Why?
|
| Neoplasms | 4 | 2007 | 2790 | 0.280 |
Why?
|
| Leiomyosarcoma | 1 | 2007 | 28 | 0.280 |
Why?
|
| Spinal Neoplasms | 1 | 2007 | 57 | 0.270 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 1314 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2023 | 889 | 0.260 |
Why?
|
| Oncolytic Viruses | 2 | 2018 | 73 | 0.250 |
Why?
|
| Neoplastic Stem Cells | 4 | 2021 | 294 | 0.250 |
Why?
|
| DNA Helicases | 2 | 2025 | 231 | 0.240 |
Why?
|
| Survival Rate | 4 | 2019 | 2062 | 0.240 |
Why?
|
| Thymidylate Synthase | 2 | 2002 | 22 | 0.230 |
Why?
|
| DNA Methylation | 3 | 2024 | 1006 | 0.230 |
Why?
|
| Pineal Gland | 1 | 2024 | 18 | 0.230 |
Why?
|
| Pinealoma | 1 | 2024 | 19 | 0.230 |
Why?
|
| Adolescent | 9 | 2024 | 19363 | 0.230 |
Why?
|
| Frontal Lobe | 1 | 2025 | 116 | 0.220 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2004 | 39 | 0.220 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 35 | 0.220 |
Why?
|
| Diskectomy, Percutaneous | 1 | 2003 | 1 | 0.220 |
Why?
|
| Cell Nucleus Structures | 1 | 2003 | 1 | 0.220 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 2513 | 0.220 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 581 | 0.220 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2003 | 18 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 144 | 0.220 |
Why?
|
| Spinal Nerve Roots | 1 | 2003 | 26 | 0.220 |
Why?
|
| Aged | 10 | 2024 | 19870 | 0.220 |
Why?
|
| Adenoma, Chromophobe | 1 | 2003 | 2 | 0.210 |
Why?
|
| Tamoxifen | 2 | 2023 | 363 | 0.210 |
Why?
|
| Radiation, Ionizing | 2 | 2014 | 41 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2018 | 3573 | 0.210 |
Why?
|
| Diagnosis, Differential | 7 | 2016 | 1897 | 0.210 |
Why?
|
| Stem Cells | 1 | 2008 | 707 | 0.210 |
Why?
|
| Human Growth Hormone | 1 | 2003 | 74 | 0.200 |
Why?
|
| Heterozygote | 1 | 2025 | 671 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 4 | 2019 | 1065 | 0.200 |
Why?
|
| Ependymoglial Cells | 1 | 2022 | 5 | 0.200 |
Why?
|
| Spinal Cord | 2 | 2017 | 302 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 173 | 0.190 |
Why?
|
| X Chromosome Inactivation | 1 | 2022 | 62 | 0.190 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 151 | 0.190 |
Why?
|
| Neuroglia | 2 | 2022 | 204 | 0.190 |
Why?
|
| Dura Mater | 1 | 2002 | 25 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 723 | 0.190 |
Why?
|
| Central Nervous System | 2 | 2014 | 255 | 0.190 |
Why?
|
| Anaphase-Promoting Complex-Cyclosome | 5 | 2008 | 20 | 0.190 |
Why?
|
| Endocrine Cells | 1 | 2021 | 1 | 0.190 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 9 | 0.190 |
Why?
|
| Thiophenes | 2 | 2000 | 70 | 0.190 |
Why?
|
| Lumbar Vertebrae | 3 | 2010 | 112 | 0.180 |
Why?
|
| Cell Proliferation | 5 | 2016 | 2311 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 762 | 0.180 |
Why?
|
| Quinazolines | 2 | 2000 | 175 | 0.180 |
Why?
|
| Amyloidosis | 1 | 2002 | 71 | 0.180 |
Why?
|
| Epithelium | 1 | 2021 | 364 | 0.180 |
Why?
|
| Cytoplasm | 1 | 2021 | 296 | 0.170 |
Why?
|
| Thymidine | 2 | 2000 | 54 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 141 | 0.170 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2013 | 234 | 0.170 |
Why?
|
| Cell Nucleus | 2 | 2021 | 676 | 0.170 |
Why?
|
| Dipyridamole | 1 | 2000 | 28 | 0.170 |
Why?
|
| Aurora Kinases | 2 | 2012 | 32 | 0.170 |
Why?
|
| Nerve Tissue Proteins | 2 | 2025 | 1112 | 0.170 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2000 | 52 | 0.160 |
Why?
|
| Child, Preschool | 6 | 2024 | 14027 | 0.160 |
Why?
|
| Mice | 8 | 2023 | 17631 | 0.160 |
Why?
|
| Carboplatin | 1 | 2019 | 76 | 0.160 |
Why?
|
| Genes, p53 | 2 | 2015 | 212 | 0.150 |
Why?
|
| Bone Cysts | 1 | 2018 | 3 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 80 | 0.150 |
Why?
|
| Cell Cycle | 3 | 2018 | 617 | 0.150 |
Why?
|
| Cellular Senescence | 2 | 2012 | 161 | 0.150 |
Why?
|
| Herpesviridae | 1 | 2018 | 33 | 0.150 |
Why?
|
| Thyroid Hormones | 1 | 2018 | 67 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2000 | 183 | 0.150 |
Why?
|
| Skull Base | 1 | 2018 | 53 | 0.150 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2018 | 33 | 0.150 |
Why?
|
| Animals | 12 | 2023 | 34232 | 0.150 |
Why?
|
| Benzazepines | 1 | 2018 | 62 | 0.140 |
Why?
|
| Spine | 1 | 2018 | 142 | 0.140 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 131 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5176 | 0.140 |
Why?
|
| Nestin | 2 | 2014 | 17 | 0.140 |
Why?
|
| Gene Order | 1 | 2017 | 79 | 0.140 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 246 | 0.140 |
Why?
|
| Image-Guided Biopsy | 1 | 2017 | 38 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2018 | 708 | 0.140 |
Why?
|
| Thoracic Vertebrae | 2 | 2010 | 68 | 0.140 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2017 | 70 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 259 | 0.130 |
Why?
|
| Phosphoproteins | 2 | 2016 | 418 | 0.130 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 183 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2023 | 837 | 0.130 |
Why?
|
| Intelligence | 1 | 2017 | 98 | 0.130 |
Why?
|
| Intracranial Aneurysm | 1 | 2017 | 89 | 0.130 |
Why?
|
| Neurofibromin 2 | 1 | 2016 | 9 | 0.130 |
Why?
|
| Hydrocortisone | 1 | 2017 | 218 | 0.130 |
Why?
|
| Infant | 5 | 2025 | 12516 | 0.130 |
Why?
|
| Textbooks as Topic | 1 | 2016 | 8 | 0.130 |
Why?
|
| Neuropathology | 1 | 2016 | 7 | 0.130 |
Why?
|
| Hepatectomy | 1 | 2017 | 112 | 0.130 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2016 | 40 | 0.130 |
Why?
|
| Atlases as Topic | 1 | 2016 | 16 | 0.130 |
Why?
|
| Cough | 1 | 2017 | 94 | 0.130 |
Why?
|
| MCF-7 Cells | 3 | 2023 | 222 | 0.120 |
Why?
|
| Genetic Loci | 1 | 2017 | 339 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 306 | 0.120 |
Why?
|
| DNA Repair | 1 | 2018 | 585 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1242 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 794 | 0.120 |
Why?
|
| Angiogenic Proteins | 1 | 2014 | 16 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 302 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 777 | 0.110 |
Why?
|
| Pleural Diseases | 1 | 2014 | 28 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 225 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2000 | 576 | 0.110 |
Why?
|
| Entropy | 1 | 2013 | 26 | 0.110 |
Why?
|
| Reoperation | 2 | 2010 | 833 | 0.110 |
Why?
|
| Melanoma | 2 | 2014 | 942 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 71 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 919 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2017 | 1506 | 0.110 |
Why?
|
| Signal Transduction | 7 | 2021 | 4534 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2018 | 1022 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1056 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 190 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 383 | 0.100 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 118 | 0.100 |
Why?
|
| Axons | 2 | 2013 | 369 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2014 | 142 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2017 | 12392 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 294 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 64 | 0.100 |
Why?
|
| Alleles | 1 | 2017 | 1614 | 0.100 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 45 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 271 | 0.100 |
Why?
|
| Brain Injuries | 2 | 2013 | 764 | 0.100 |
Why?
|
| Gene Dosage | 1 | 2013 | 440 | 0.090 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2011 | 9 | 0.090 |
Why?
|
| Substrate Specificity | 2 | 2009 | 295 | 0.090 |
Why?
|
| Proteins | 2 | 2007 | 1036 | 0.090 |
Why?
|
| Antigens, CD | 3 | 2010 | 432 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2018 | 1527 | 0.090 |
Why?
|
| Dendrites | 1 | 2012 | 196 | 0.090 |
Why?
|
| Sacrum | 1 | 2010 | 29 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 130 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 166 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1726 | 0.080 |
Why?
|
| Proteomics | 1 | 2013 | 502 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 647 | 0.080 |
Why?
|
| Cranial Irradiation | 1 | 2010 | 67 | 0.080 |
Why?
|
| Neuronal Plasticity | 1 | 2012 | 272 | 0.080 |
Why?
|
| Microscopy, Electron | 1 | 2010 | 396 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2016 | 398 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 4817 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 122 | 0.080 |
Why?
|
| Transcriptome | 1 | 2016 | 954 | 0.080 |
Why?
|
| Demyelinating Diseases | 1 | 2009 | 64 | 0.080 |
Why?
|
| Blood Volume | 1 | 2009 | 81 | 0.080 |
Why?
|
| Cadherins | 2 | 2007 | 171 | 0.080 |
Why?
|
| Folic Acid Antagonists | 2 | 2002 | 16 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2010 | 111 | 0.080 |
Why?
|
| Time Factors | 3 | 2017 | 6338 | 0.080 |
Why?
|
| Cytochrome P-450 CYP4A | 1 | 2008 | 2 | 0.080 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2008 | 6 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2013 | 1102 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 2522 | 0.070 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2008 | 24 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2008 | 82 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 1275 | 0.070 |
Why?
|
| E2F Transcription Factors | 1 | 2007 | 24 | 0.070 |
Why?
|
| Spinal Canal | 1 | 2007 | 5 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 123 | 0.070 |
Why?
|
| Molecular Chaperones | 1 | 2008 | 167 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2011 | 697 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2008 | 195 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2107 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 2057 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 862 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 249 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2007 | 329 | 0.070 |
Why?
|
| Polyploidy | 1 | 2006 | 15 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3157 | 0.070 |
Why?
|
| NIH 3T3 Cells | 1 | 2006 | 91 | 0.070 |
Why?
|
| Brain Diseases | 1 | 2009 | 300 | 0.060 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 111 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2006 | 79 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 897 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2820 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 620 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6598 | 0.060 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2004 | 18 | 0.060 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2004 | 16 | 0.060 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2004 | 10 | 0.060 |
Why?
|
| Genomic Instability | 1 | 2006 | 229 | 0.060 |
Why?
|
| Cell Line | 2 | 2007 | 2756 | 0.060 |
Why?
|
| Fatty Acids | 2 | 2024 | 344 | 0.060 |
Why?
|
| DNA Damage | 1 | 2007 | 513 | 0.060 |
Why?
|
| Stroke | 1 | 2012 | 989 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 1659 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 419 | 0.050 |
Why?
|
| Cell Survival | 3 | 2018 | 813 | 0.050 |
Why?
|
| Intervertebral Disc | 1 | 2003 | 12 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2007 | 547 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2006 | 356 | 0.050 |
Why?
|
| Acromegaly | 1 | 2003 | 8 | 0.050 |
Why?
|
| Arachnoid | 1 | 2003 | 8 | 0.050 |
Why?
|
| Cadaver | 1 | 2003 | 132 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2023 | 723 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 1290 | 0.050 |
Why?
|
| Subarachnoid Space | 1 | 2003 | 24 | 0.050 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2002 | 9 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2003 | 96 | 0.050 |
Why?
|
| Microglia | 1 | 2024 | 102 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 230 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2023 | 163 | 0.050 |
Why?
|
| Biomarkers | 1 | 2012 | 3091 | 0.050 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2003 | 77 | 0.050 |
Why?
|
| 3-Hydroxyacyl CoA Dehydrogenases | 1 | 2002 | 9 | 0.050 |
Why?
|
| Meninges | 1 | 2002 | 18 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2002 | 184 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 89 | 0.050 |
Why?
|
| CD24 Antigen | 1 | 2021 | 29 | 0.050 |
Why?
|
| Hyaluronan Receptors | 1 | 2021 | 66 | 0.050 |
Why?
|
| Rats | 3 | 2013 | 3727 | 0.050 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2002 | 117 | 0.040 |
Why?
|
| Adenosine | 1 | 2021 | 127 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 506 | 0.040 |
Why?
|
| Swine | 1 | 2003 | 1210 | 0.040 |
Why?
|
| Macrophages | 1 | 2024 | 625 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1360 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2014 | 359 | 0.040 |
Why?
|
| Ki-67 Antigen | 2 | 2010 | 113 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 949 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2000 | 257 | 0.040 |
Why?
|
| Benign Paroxysmal Positional Vertigo | 1 | 2018 | 8 | 0.040 |
Why?
|
| Cyclin E | 2 | 2008 | 30 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 2067 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2021 | 458 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 119 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 1016 | 0.040 |
Why?
|
| Immunity | 1 | 2018 | 192 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1998 | 294 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2012 | 16353 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 122 | 0.030 |
Why?
|
| Kinetics | 1 | 2018 | 1333 | 0.030 |
Why?
|
| Papilloma | 1 | 2016 | 26 | 0.030 |
Why?
|
| X-linked Nuclear Protein | 1 | 2016 | 17 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 489 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1697 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2015 | 59 | 0.030 |
Why?
|
| Telomerase | 1 | 2016 | 160 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 140 | 0.030 |
Why?
|
| Vero Cells | 1 | 2014 | 109 | 0.030 |
Why?
|
| Telomere | 1 | 2016 | 214 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2016 | 462 | 0.030 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 1993 | 5 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 1711 | 0.030 |
Why?
|
| Tetrahydrofolates | 1 | 1993 | 17 | 0.030 |
Why?
|
| Diffusion | 1 | 2013 | 57 | 0.030 |
Why?
|
| Acyltransferases | 1 | 1993 | 44 | 0.030 |
Why?
|
| Oncolytic Virotherapy | 1 | 2014 | 85 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2014 | 135 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 208 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 85 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 1460 | 0.030 |
Why?
|
| Probability | 1 | 2013 | 320 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 676 | 0.020 |
Why?
|
| Neurofilament Proteins | 1 | 2012 | 28 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2013 | 171 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2012 | 57 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1328 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2012 | 63 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 292 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 58 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 686 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2012 | 227 | 0.020 |
Why?
|
| Oligodendroglia | 1 | 2012 | 76 | 0.020 |
Why?
|
| Myelin Sheath | 1 | 2012 | 122 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2012 | 381 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2003 | 3073 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 678 | 0.020 |
Why?
|
| Anisotropy | 1 | 2010 | 121 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 26 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2010 | 35 | 0.020 |
Why?
|
| Inflammation | 1 | 2017 | 1446 | 0.020 |
Why?
|
| Blood Volume Determination | 1 | 2009 | 10 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2010 | 58 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1265 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 584 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 256 | 0.020 |
Why?
|
| Phenacetin | 1 | 1989 | 3 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1755 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2012 | 3056 | 0.020 |
Why?
|
| Mutagens | 1 | 1989 | 84 | 0.020 |
Why?
|
| Perfusion | 1 | 2009 | 207 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2008 | 9 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 983 | 0.020 |
Why?
|
| Acetaminophen | 1 | 1989 | 92 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 145 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2010 | 370 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2174 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 343 | 0.020 |
Why?
|
| Aspirin | 1 | 1989 | 221 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2009 | 398 | 0.020 |
Why?
|
| GTPase-Activating Proteins | 1 | 2007 | 86 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2007 | 391 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 627 | 0.020 |
Why?
|
| Interphase | 1 | 2006 | 46 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2006 | 192 | 0.020 |
Why?
|
| Peptides | 1 | 2010 | 811 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 463 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2006 | 200 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 412 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 1069 | 0.020 |
Why?
|
| Contrast Media | 1 | 2009 | 480 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 1238 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2006 | 291 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 573 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2013 | 8233 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 867 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 284 | 0.010 |
Why?
|
| Pons | 1 | 2004 | 32 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 806 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 794 | 0.010 |
Why?
|
| Neurons | 1 | 2014 | 1931 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 1560 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 837 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 1756 | 0.010 |
Why?
|
| Mitochondrial Trifunctional Protein | 1 | 2002 | 1 | 0.010 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2002 | 94 | 0.010 |
Why?
|
| Head Injuries, Closed | 1 | 1998 | 46 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1998 | 125 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 1998 | 205 | 0.010 |
Why?
|
| Phosphoribosylglycinamide Formyltransferase | 1 | 1993 | 1 | 0.010 |
Why?
|
| Hypoxanthines | 1 | 1993 | 4 | 0.010 |
Why?
|
| Hypoxanthine | 1 | 1993 | 7 | 0.010 |
Why?
|
| Cell Division | 1 | 1993 | 781 | 0.010 |
Why?
|
| Methotrexate | 1 | 1993 | 334 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1993 | 248 | 0.010 |
Why?
|
| Mutagenicity Tests | 1 | 1989 | 36 | 0.000 |
Why?
|
| Biotransformation | 1 | 1989 | 50 | 0.000 |
Why?
|
| Pregnancy | 1 | 2002 | 7207 | 0.000 |
Why?
|
| Mice, Inbred C3H | 1 | 1989 | 115 | 0.000 |
Why?
|
| Microsomes, Liver | 1 | 1989 | 91 | 0.000 |
Why?
|
| Clone Cells | 1 | 1989 | 166 | 0.000 |
Why?
|
| Cricetinae | 1 | 1989 | 422 | 0.000 |
Why?
|